

CITATION REPORT

List of articles citing

The pharmacology of cannabinoid receptors and their ligands: an overview

DOI: 10.1038/sj.ijo.0803272

International Journal of Obesity, 2006, 30 Suppl 1, S13-8.

Source: <https://exaly.com/paper-pdf/39756850/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
403	Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2,4-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. 2006 , 49, 7502-12		62
402	Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol. 2006 , 188, 306-14		25
401	Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol. 2006 , 319, 1211-8		43
400	Cannabinoids: a new group of agonists of PPARs. 2007 , 2007, 23513		69
399	The emerging functions of endocannabinoid signaling during CNS development. 2007 , 28, 83-92		289
398	Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence. 2007 , 56, 406-17		17
397	Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model. 2007 , 50, 5951-66		52
396	Analgesic, Anti-inflammatory, and Anti-pyretic Activity. 2007 , 983-1116		2
395	CP55940. 2007 , 1-3		
394	The N-acylethanolamine-mediated regulatory pathway in plants. 2007 , 4, 1933-55		57
393	Simultaneous quantification of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact mass spectrometry. 2007 , 1163, 318-27		63
392	Delta 9-tetrahydrocannabinol inhibits electrically-evoked CGRP release and capsaicin-sensitive sensory neurogenic vasodilatation in the rat mesenteric arterial bed. 2007 , 152, 709-16		10
391	The cannabinoid CB(2) receptor: a good friend in the gut. 2007 , 19, 704-8		38
390	Role of Ca ²⁺ -dependent potassium channels in in vitro anandamide-mediated mesenteric vasorelaxation in rats with biliary cirrhosis. 2007 , 27, 1045-55		15
389	Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity. 2007 , 9, 365-73		16
388	Current and novel therapies for the treatment of nonalcoholic steatohepatitis. 2007 , 1, 343-54		5
387	Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. 2008 , 58, 145-53		72

386	Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. 2008 , 155, 913-24	46
385	Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. 2008 , 153, 367-79	74
384	In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints. 2008 , 153, 358-66	31
383	Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. 2008 , 153, 252-62	159
382	The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. 2008 , 89, 384-91	37
381	Clarifying CB2 receptor-dependent and independent effects of THC on human lung epithelial cells. 2008 , 231, 282-90	11
380	CB1 Cannabinoid Receptors: Molecular Biology, Second Messenger Coupling and Polarized Trafficking in Neurons. 2008 , 59-73	5
379	Synthesis and Cannabinoid Activity of a Variety of 2,3-Substituted 1-Benzo[b]thiophen Derivatives and 2,3-Substituted Benzofuran: Novel Agonists for the CB1 Receptor. 2008 , 61, 484	5
378	Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats. 2008 , 55, 1183-90	27
377	Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. 2008 , 93, 671-86	77
376	Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model. 2008 , 51, 2439-46	52
375	Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity. 2008 , 51, 2115-27	39
374	Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. 2009 , 50, 3-21	377
373	Novedades sobre el cannabis. 2009 , 16, 204-212	
372	Exercise and bipolar disorder: a review of neurobiological mediators. 2009 , 11, 328-36	38
371	Beneficial effects of a Cannabis sativa extract treatment on diabetes-induced neuropathy and oxidative stress. 2009 , 23, 1678-84	39
370	The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. <i>International Journal of Obesity</i> , 2009 , 33 Suppl 2, S18-24	5.5 131
369	Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2. 2009 , 101, 940-50	71

368	D2 receptor-mediated inhibition of dopamine release in the rat striatum in vitro is modulated by CB1 receptors: studies using fast cyclic voltammetry. 2009 , 108, 545-51	16
367	Analogues of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity. 2009 , 44, 593-608	16
366	Hit-to-lead optimization of pyrrolo[1,2-a]quinoxalines as novel cannabinoid type 1 receptor antagonists. 2009 , 19, 3471-5	27
365	Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. 2009 , 14, 43-65	141
364	Solid-state NMR and molecular dynamics characterization of cannabinoid receptor-1 (CB1) helix 7 conformational plasticity in model membranes. 2009 , 1788, 1159-67	17
363	Structural biology of human cannabinoid receptor-2 helix 6 in membrane-mimetic environments. 2009 , 384, 243-8	15
362	Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. 2009 , 33, 1517-21	102
361	Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. 2009 , 161, 655-62	38
360	Encyclopedia of Neuroscience. 2009 , 525-928	2
359	The cannabinoid R+ methanandamide induces IL-6 secretion by prostate cancer PC3 cells. 2009 , 6, 249-56	14
358	Comorbid mood, psychosis, and marijuana abuse disorders: a theoretical review. 2009 , 28, 309-19	24
357	Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. 2009 , 23, 597-602	117
356	In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. 2010 , 398, 2141-53	121
355	The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. 2010 , 221, 32-41	28
354	AM 251 differentially effects food-maintained responding depending on food palatability. 2010 , 95, 443-8	16
353	Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice. 2010 , 637, 62-9	30
352	Systemic cannabinoids produce CB1-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT(7) and 5-HT(2A) receptors. 2010 , 649, 183-94	48
351	The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A3 adenosine receptor. 2010 , 79, 48-56	39

350	The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats. 2010 , 1363, 40-8	32
349	Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. 2010 , 77, 1-9	90
348	Biologically Active Compounds in Food Products and Their Effects on Obesity and Diabetes. 2010 , 509-545	5
347	Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance. 2010 , 215, 629-46	59
346	Cannabinoids and the immune system: an overview. 2010 , 215, 588-97	159
345	Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists. 2010 , 10, 547-55	37
344	Effects of cannabinoids on capsaicin receptor activity following exposure of primary sensory neurons to inflammatory mediators. 2010 , 87, 162-8	11
343	Retrograde release of endocannabinoids inhibits presynaptic GABA release to second-order baroreceptive neurons in NTS. 2010 , 158, 44-50	19
342	Epidermal growth factor receptor transactivation by the cannabinoid receptor (CB1) and transient receptor potential vanilloid 1 (TRPV1) induces differential responses in corneal epithelial cells. 2010 , 91, 462-71	72
341	Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists. 2010 , 58, 1215-9	10
340	Cannabinoid-hormone interactions in the regulation of motivational processes. 2010 , 58, 100-10	50
339	Chemistry of Cannabis. 2010 , 1033-1084	18
338	Pre-training anandamide infusion within the basolateral amygdala impairs plus-maze discriminative avoidance task in rats. 2011 , 95, 527-33	14
337	A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells. 2011 , 63, 636-47	14
336	The function of the endocannabinoid system. 23-34	
335	A Pilot Study into the Effects of the CB1 Cannabinoid Receptor Agonist WIN55,212-2 or the Antagonist/Inverse Agonist AM251 on Sleep in Rats. 2011 , 2011, 178469	13
334	Binding properties of antagonists to cannabinoid receptors in intact cells. 2011 , 25, 200-10	12
333	Intra-accumbal NMDA but not AMPA/kainate receptor antagonist attenuates WIN55,212-2 cannabinoid receptor agonist-induced antinociception in the basolateral amygdala in a rat model of acute pain. 2011 , 100, 213-9	28

332	Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice. 2011 , 215, 455-65	29
331	Endocannabinoids regulate the migration of subventricular zone-derived neuroblasts in the postnatal brain. 2011 , 31, 4000-11	80
330	Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. 2011 , 3, 350-60	18
329	Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure. 2011 , 27, 427-35	19
328	Novel identified receptors on mast cells. 2012 , 3, 238	56
327	Cannabinoid receptor activation correlates with the proapoptotic action of the β -adrenergic agonist (R,R)-4-methoxy-1-naphthylfenoterol in HepG2 hepatocarcinoma cells. 2012 , 343, 157-66	12
326	Off-target cannabinoid effects mediated by GPR55. 2012 , 89, 179-87	49
325	Anti-obesity drugs: past, present and future. 2012 , 5, 621-6	306
324	Cannabis, a complex plant: different compounds and different effects on individuals. 2012 , 2, 241-54	222
323	Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke. 2012 , 207, 307-15	39
322	Cannabinoids: novel therapies for arthritis?. 2012 , 4, 713-25	11
321	Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-c]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold Hopping. 2012 , 6, 1-14	8
320	Anandamide induces matrix metalloproteinase-2 production through cannabinoid-1 receptor and transient receptor potential vanilloid-1 in human dental pulp cells in culture. 2012 , 38, 786-90	13
319	Altered calcium regulation by thermosensitive transient receptor potential channels in etoposide-resistant WERI-Rb1 retinoblastoma cells. 2012 , 94, 157-73	30
318	The Action of Plants and their Constituents on the Central Nervous System. 2012 , 161-204	4
317	The safety of studies with intravenous Δ^9 -tetrahydrocannabinol in humans, with case histories. 2012 , 219, 885-96	26
316	Effects of glutamate NMDA and TRPV1 receptor antagonists on the biphasic responses to anandamide injected into the dorsolateral periaqueductal grey of Wistar rats. 2013 , 226, 579-87	18
315	Feasibility of targeting ischaemia-related ventricular arrhythmias by mimicry of endogenous protection by endocannabinoids. 2013 , 169, 1840-8	11

314	Reduced expression of brain cannabinoid receptor 1 (Cnr1) is coupled with an increased complementary micro-RNA (miR-26b) in a mouse model of fetal alcohol spectrum disorders. 2013 , 5, 14	28
313	Novel pyrazole derivatives as neutral CB1 antagonists with significant activity towards food intake. 2013 , 62, 256-69	22
312	NESS06SM reduces body weight with an improved profile relative to SR141716A. 2013 , 74, 94-108	25
311	Cannabis, psychosis and the thalamus: a theoretical review. 2013 , 37, 658-67	10
310	Synthetic cannabinoid intoxication: a case series and review. 2013 , 44, 360-6	180
309	Cannabis and Hallucinations: Studies in Human Subjects. 2013 , 279-288	
308	Effects of Schedule I drug laws on neuroscience research and treatment innovation. 2013 , 14, 577-85	178
307	The cannabinoid WIN 55,212-2 decreases specificity protein transcription factors and the oncogenic cap protein eIF4E in colon cancer cells. 2013 , 12, 2483-93	27
306	Treatment failure of intrathecal baclofen and supra-additive effect of nabiximols in multiple sclerosis-related spasticity: a case report. 2013 , 6, 199-203	4
305	The role of endocannabinoids in pregnancy. 2013 , 146, R101-9	17
304	Fascin regulates the migration of subventricular zone-derived neuroblasts in the postnatal brain. 2013 , 33, 12171-85	42
303	Neuropeptide Receptors. 2013 , 2, 1-167	2
302	Understanding the molecular aspects of tetrahydrocannabinol and cannabidiol as antioxidants. 2013 , 18, 12663-74	61
301	PUFA-derived endocannabinoids: an overview. 2013 , 72, 451-9	16
300	The effect of cannabis use on memory function: an update. 2013 , 4, 11-27	53
299	Antidepressants: TCAs and SNRIs. 217-224	
298	Cannabinoids. 249-266	
297	The effect of the cannabinoid CB1 receptor agonist arachidonylcyclopropylamide (ACPA) on behavioural sensitisation to methamphetamine in mice. 2014 , 59, 88-94	2

296	Relevance of gap junctions and large pore channels in traumatic brain injury. 2014 , 5, 31	9
295	Cannabinoid-dependent potentiation of inhibition at eye opening in mouse V1. 2014 , 8, 46	19
294	Coumarin derivatives: an updated patent review (2012-2014). 2014 , 24, 1323-47	41
293	Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB1 Receptors: A Step Back into the Future. 2014 , 5, 92	57
292	Effects of endogenous cannabinoid anandamide on excitation-contraction coupling in rat ventricular myocytes. 2014 , 55, 104-18	13
291	Optimization of chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1). 2014 , 57, 3040-52	43
290	Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists. 2014 , 79, 298-339	47
289	Dronabinol and chronic pain: importance of mechanistic considerations. 2014 , 15, 1525-34	19
288	Permanent suppression of cortical oscillations in mice after adolescent exposure to cannabinoids: receptor mechanisms. 2014 , 86, 161-73	28
287	Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCBR selective benzimidazoles reveal unexpected intrinsic properties. 2014 , 22, 3938-46	15
286	Acute kidney injury associated with smoking synthetic cannabinoid. 2014 , 52, 664-73	82
285	Preoperative paracetamol infusion reduces sevoflurane consumption during thyroidectomy under general anesthesia with spectral entropy monitoring Available online 15 January 2014 View all notes. 2014 , 30, 115-122	7
284	The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys. 2014 , 727, 35-42	14
283	The inhibitory effect of anandamide on oxytocin and vasopressin secretion from neurohypophysis is mediated by nitric oxide. 2014 , 188, 31-9	15
282	Augmented tonic pain-related behavior in knockout mice lacking monoacylglycerol lipase, a major degrading enzyme for the endocannabinoid 2-arachidonoylglycerol. 2014 , 271, 51-8	13
281	Driving under the influence of synthetic cannabinoids ("Spice"): a case series. 2014 , 128, 59-64	87
280	Endogenous vs Exogenous Allosteric Modulators in GPCRs: A dispute for shuttling CB1 among different membrane microenvironments. 2015 , 5, 15453	32
279	Primary Macrophage Chemotaxis Induced by Cannabinoid Receptor 2 Agonists Occurs Independently of the CB2 Receptor. 2015 , 5, 10682	21

278	The Endocannabinoid System and Its Role in Regulating the Intrinsic Neural Circuitry of the Gastrointestinal Tract. 2015 , 125, 85-126	15
277	Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model. 2015 , 25, 587-92	9
276	Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds. 2015 , 25, 581-6	11
275	Cannabinoid receptor interacting protein (CRIP1a) attenuates CB1R signaling in neuronal cells. 2015 , 27, 716-726	29
274	Common single nucleotide variants underlying drug addiction: more than a decade of research. 2015 , 20, 845-71	70
273	Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. 2015 , 5, 7642	75
272	A potential role for cannabinoid receptors in the therapeutic action of fenofibrate. 2015 , 29, 1446-55	28
271	Cannabis and Bioactive Cannabinoids. 2015 , 17-57	2
270	Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice. 2015 , 150, 31-7	15
269	Regional effects of endocannabinoid, BDNF and FGF receptor signalling on neuroblast motility and guidance along the rostral migratory stream. 2015 , 64, 32-43	18
268	Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?. 2015 , 12, 778-87	23
267	Dronabinol treatment of refractory nausea and vomiting related to peritoneal carcinomatosis. 2015 , 32, 5-7	9
266	Reactions of CF3-enones with arenes under superelectrophilic activation: a pathway to trans-1,3-diaryl-1-CF3-indanes, new cannabinoid receptor ligands. 2015 , 13, 8827-42	27
265	Fluorescent knock-in mice to decipher the physiopathological role of G protein-coupled receptors. 2014 , 5, 289	7
264	Acute activation of cannabinoid receptors by anandamide reduces gastrointestinal motility and improves postprandial glycemia in mice. 2015 , 64, 808-18	16
263	Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators. 2015 , 23, 2195-2203	29
262	Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture. 2015 , 112, E6185-94	33
261	Pharmacotherapy for the treatment of obesity. 2015 , 418 Pt 2, 173-83	23

260	Thiazole: a promising heterocycle for the development of potent CNS active agents. 2015 , 92, 1-34	98
259	Beyond radio-displacement techniques for identification of CB1 ligands: the first application of a fluorescence-quenching assay. 2014 , 4, 3757	14
258	Delayed, persistent, serotonin syndrome and ileus with multiple organ failure after SpiceQ ingestion. 2016 , 4, 109-113	
257	Overview of Cannabis Use, Misuse, and Addiction. 2016 , 665-671	
256	The Endocannabinoid System as a Therapeutic Target in Glaucoma. 2016 , 2016, 9364091	35
255	Cannabinoids and Cytochrome P450 Interactions. 2016 , 17, 206-26	137
254	Interaction between Tat and Drugs of Abuse during HIV-1 Infection and Central Nervous System Disease. 2015 , 6, 1512	13
253	Medullary Endocannabinoids Contribute to the Differential Resting Baroreflex Sensitivity in Rats with Altered Brain Renin-Angiotensin System Expression. 2016 , 7, 207	7
252	A user's guide to cannabinoid therapies in oncology. 2016 , 23, 398-406	44
251	G protein coupled receptor 18: A potential role for endocannabinoid signaling in metabolic dysfunction. 2016 , 60, 92-102	24
250	Role of endocannabinoids in the progression of diabetic retinopathy. 2016 , 32, 251-9	6
249	Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. 2016 , 18, 558-70	92
248	Targeting the Endocannabinoid System in Psychiatric Illness. 2016 , 36, 691-703	21
247	Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. 2016 , 112, 104-15	60
246	Behavioral sensitization to ethanol: Neural basis and factors that influence its acquisition and expression. 2016 , 125, 53-78	40
245	Lipid Regulation of Sodium Channels. 2016 , 78, 353-407	8
244	Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis. 2016 , 339, 433-449	22
243	Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor. 2016 , 124, 17-35	17

242	Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents. 2016 , 122, 723-730	47
241	Exocannabinoids effect on in vitro bovine oocyte maturation via activation of AKT and ERK1/2. 2016 , 152, 603-612	13
240	Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids. 2017 , 32, 231-248	19
239	GPR55 - a putative "type 3" cannabinoid receptor in inflammation. 2016 , 27, 297-302	53
238	Discriminative Stimulus Properties of Phytocannabinoids, Endocannabinoids, and Synthetic Cannabinoids. 2018 , 39, 153-173	10
237	Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs. 2018 , 39, 261-295	4
236	The Pharmacological Basis of Cannabis Therapy for Epilepsy. 2016 , 357, 45-55	75
235	Cannabinoid receptor 1 ligands revisited: Pharmacological assessment in the ACTOne system. 2016 , 498, 8-28	6
234	Cannabinoid pharmacology in cancer research: A new hope for cancer patients?. 2016 , 775, 1-14	45
233	Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. 2016 , 62, 107-28	203
232	Ligands for cannabinoid receptors, promising anticancer agents. 2016 , 146, 124-30	31
231	Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs. 2016 , 54, 14-9	18
230	Synergistic effect between prelimbic 5-HT ₃ and CB1 receptors on memory consolidation deficit in adult male Sprague-Dawley rats: An isobologram analysis. 2016 , 317, 173-83	12
229	A Novel Radiotracer for Imaging Monoacylglycerol Lipase in the Brain Using Positron Emission Tomography. 2016 , 7, 484-9	32
228	New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking. 2017 , 127, 398-412	12
227	Antihyperalgesic effect of CB receptor activation involves the modulation of P2X receptor in the primary afferent neuron. 2017 , 798, 113-121	19
226	Combined CoMFA and CoMSIA 3D-QSAR study of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor. 2017 , 101, 1-10	18
225	Cannabinoid signaling in health and disease. 2017 , 95, 311-327	67

224	Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor. 2017 , 119, 391-403	22
223	G protein-coupled receptor 55 (GPR55) expresses differently in patients with Crohn's disease and ulcerative colitis. 2017 , 52, 711-715	11
222	Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments. 2017 , 75, 157-165	56
221	Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. 2017 , 70, 319-327	102
220	Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis. 2017 , 116, 77-84	70
219	Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. 2017 , 124, 3-12	50
218	Analysis of natural product regulation of cannabinoid receptors in the treatment of human disease. 2017 , 180, 24-48	16
217	Apparent CB Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model. 2017 , 362, 210-218	15
216	The Endocannabinoid System in Local and Systemic Inflammation. 2017 , 9, i-192	1
215	Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. 2017 , 42, 1752-1765	132
214	Dried haematic microsamples and LC-MS/MS for the analysis of natural and synthetic cannabinoids. 2017 , 1044-1045, 77-86	38
213	The northeast regional SPS meeting update: Safety pharmacology innovations and applications. 2017 , 85, 82-86	4
212	Psychoactive Drugs. 2017 , 363-374	2
211	CB2 receptors regulate natural killer cells that limit allergic airway inflammation in a murine model of asthma. 2017 , 72, 937-947	29
210	Human serum albumin: A modulator of cannabinoid drugs. 2017 , 69, 834-840	12
209	Effects of the cannabinoid CB agonist ACEA on salicylate ototoxicity, hyperacusis and tinnitus in guinea pigs. 2017 , 356, 51-62	14
208	Characterization of structurally novel G protein biased CB agonists: Implications for drug development. 2017 , 125, 161-177	25
207	The potential role of cannabinoids in epilepsy treatment. 2017 , 17, 1069-1079	16

206	Immunolocalization of cannabinoid receptor type 1 and CB2 cannabinoid receptors, and transient receptor potential vanilloid channels in pterygium. 2017 , 16, 5285-5293	7
205	Effects of cannabidiol interactions with Wnt/ β -catenin pathway and PPAR β on oxidative stress and neuroinflammation in Alzheimer's disease. 2017 , 49, 853-866	102
204	Highly selective CB receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice. 2017 , 390, 1015-1027	10
203	Endocannabinoids in arthritis: current views and perspective. 2017 , 20, 789-797	9
202	Structure-Affinity Relationships and Structure-Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists. 2017 , 60, 9545-9564	5
201	Postnatal development of neurotransmitter systems and their relevance to extinction of conditioned fear. 2017 , 138, 252-270	27
200	Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites. 2017 , 101, 239-253	64
199	Synthetic Cannabinoid Receptor Agonists (Spice) as New Recreational Psychoactive Substances. 2017 , 839-847	1
198	Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer. 2017 , 8, 29668-29678	31
197	The Ratio of 2-AG to Its Isomer 1-AG as an Intrinsic Fine Tuning Mechanism of CB1 Receptor Activation. 2017 , 11, 39	16
196	Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system. 2017 , 12, e0181064	36
195	In Vitro and in Vivo Evaluation of C-Labeled Azetidinecarboxylates for Imaging Monoacylglycerol Lipase by PET Imaging Studies. 2018 , 61, 2278-2291	29
194	Cannabinoids and cancer pain: A new hope or a false dawn?. 2018 , 49, 30-36	19
193	Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands. 2018 , 13, 1102-1114	1
192	The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents. 2018 , 8, 2416	42
191	Cannabinoids and glial cells: possible mechanism to understand schizophrenia. 2018 , 268, 727-737	9
190	Cannabidiol in Pediatric Epilepsy. 2018 , 6, 26-29	1
189	Peripheral modulation of the endocannabinoid system in metabolic disease. 2018 , 23, 592-604	25

188	Developmental Effects of Cannabidiol and Δ^9 -Tetrahydrocannabinol in Zebrafish. 2018 , 162, 137-145	26
187	Pharmacological evaluation of new constituents of "Spice": synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds. 2018 , 36, 385-403	64
186	Residual effects of cannabis use in adolescent and adult brains - A meta-analysis of fMRI studies. 2018 , 88, 26-41	52
185	Δ^9 -Tetrahydrocannabinol induces endocannabinoid accumulation in mouse hepatocytes: antagonism by gene ablation. 2018 , 59, 646-657	11
184	Drug-drug interactions as a result of co-administering Δ^9 THC and CBD with other psychotropic agents. 2018 , 17, 51-54	49
183	Natural product modulators of human sensations and mood: molecular mechanisms and therapeutic potential. 2018 , 47, 1592-1637	18
182	The endocannabinoid system in cardiovascular function: novel insights and clinical implications. 2018 , 28, 35-52	25
181	Crosstalk Between Nitric Oxide and Endocannabinoid Signaling Pathways in Normal and Pathological Placentation. 2018 , 9, 1699	9
180	Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations. 2018 , 8, 13787	21
179	Structural and Functional Interaction of Δ^9 -Tetrahydrocannabinol with Liver Fatty Acid Binding Protein (FABP1). 2018 , 57, 6027-6042	5
178	Therapeutic potential of cannabidiol and its underlying mechanisms. 2018 , 9, 112-125	0
177	Zebrafish as an alternative method for determining the embryo toxicity of plant products: a systematic review. 2018 , 25, 35015-35026	13
176	Investigational cannabinoids in seizure disorders, what have we learned thus far?. 2018 , 27, 535-541	6
175	Study of cannabinoid receptor 2 Q63R gene polymorphism in Lebanese patients with rheumatoid arthritis. 2018 , 37, 2933-2938	9
174	The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2. 2018 , 18, 34-51	24
173	Hedonic Eating and the "Delicious Circle": From Lipid-Derived Mediators to Brain Dopamine and Back. 2018 , 12, 271	52
172	Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis. 2018 , 61, 10345-10374	36
171	Modulation of the Oxidative Stress and Lipid Peroxidation by Endocannabinoids and Their Lipid Analogues. 2018 , 7,	40

170	Therapeutic applications of cannabinoids. 2018 , 293, 77-88	39
169	Cannabidiol for epilepsy: a new indication for an old drug. 2018 , 13, 181-190	1
168	Cannabidiol in Refractory Epilepsy. 2018 , 58, 419-438	1
167	Role of Natural Killer Cells in Airway Inflammation. 2018 , 10, 448-456	14
166	The tamoxifen derivative ridaifen-B is a high affinity selective CB receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects. 2018 , 353, 31-42	6
165	The endocannabinoid system in canine Steroid-Responsive Meningitis-Arteritis and Intraspinial Spirocercosis. 2018 , 13, e0187197	12
164	Computational Aids for Assessing Bioactivities. 2018 , 277-300	3
163	Screening, quantification, and confirmation of synthetic cannabinoid metabolites in urine by UHPLC-QTOF-MS. 2019 , 11, 51-67	22
162	New Insights in Cannabinoid Receptor Structure and Signaling. 2019 , 12, 239-248	32
161	Facts vs Fiction: the Role of Cannabinoids in the Treatment of Glaucoma. 2019 , 7, 177-181	4
160	Can we seize the gut microbiota to treat epilepsy?. 2019 , 107, 750-764	37
159	A Mechanistic and Pathophysiological Approach for Stroke Associated with Drugs of Abuse. 2019 , 8,	54
158	Synthetic Cannabinoid Receptor Agonists Detection Using Fluorescence Spectral Fingerprinting. 2019 , 91, 12971-12979	4
157	Gga-miR-19b-3p Inhibits Newcastle Disease Virus Replication by Suppressing Inflammatory Response via Targeting RNF11 and ZMYND11. 2019 , 10, 2006	9
156	Design, Synthesis, and Evaluation of F-Labeled Monoacylglycerol Lipase Inhibitors as Novel Positron Emission Tomography Probes. 2019 , 62, 8866-8872	11
155	Prescription Synthetic Oral Cannabinoid use Among Older Adults with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. 2019 , 36, 1035-1045	3
154	Molecular neuroscience at its "high": bibliometric analysis of the most cited papers on endocannabinoid system, cannabis and cannabinoids. 2019 , 1, 4	3
153	A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis. 2019 , 45, 506-513	8

152	Altered Swimming Behaviors in Zebrafish Larvae Lacking Cannabinoid Receptor 2. 2019 , 4, 88-101	6
151	Structural Insights into CB1 Receptor Biased Signaling. 2019 , 20,	43
150	Design, Synthesis, and Evaluation of Reversible and Irreversible Monoacylglycerol Lipase Positron Emission Tomography (PET) Tracers Using a "Tail Switching" Strategy on a Piperazinyl Azetidine Skeleton. 2019 , 62, 3336-3353	18
149	Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease. 2019 , 4, 10-20	11
148	Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ^9 Tetrahydrocannabinol and JWH-018. 2019 , 369, 259-269	2
147	Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. 2019 , 236, 2677-2685	17
146	Aging circadian rhythms and cannabinoids. 2019 , 79, 110-118	16
145	Biologands Acting on the Cannabinoid Receptor CB1 for the Treatment of Withdrawal Syndrome Caused by Cannabis sativa. 2019 ,	
144	Experimental Cannabinoid 2 Receptor Activation by Phyto-Derived and Synthetic Cannabinoid Ligands in LPS-Induced Interstitial Cystitis in Mice. 2019 , 24,	16
143	Cannabis Influences the Putative Cytokines-Related Pathway of Epilepsy among Egyptian Epileptic Patients. 2019 , 9,	5
142	Evidence for a GPR18 Role in Chemotaxis, Proliferation, and the Course of Wound Closure in the Cornea. 2019 , 38, 905-913	9
141	Introducing nitrogen atoms to amidoalkylindoles: potent and selective cannabinoid type 2 receptor agonists with improved aqueous solubility. 2019 , 10, 2131-2139	4
140	Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies. 2019 , 174, 53-89	137
139	Cannabinoids, Chemical Senses, and Regulation of Feeding Behavior. 2019 , 44, 73-89	7
138	Δ^9 Tetrahydrocannabinol, a major marijuana component, enhances the anesthetic effect of pentobarbital through the CB receptor. 2019 , 37, 207-214	3
137	Microbial regulation of organismal energy homeostasis. 2019 , 1, 34-46	186
136	A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis. 2019 , 29, 330-348	20
135	Mechanisms underlying select chemotherapeutic-agent-induced neuroinflammation and subsequent neurodegeneration. 2019 , 842, 49-56	14

134	Medical cannabis for chronic pain: can it make a difference in pain management?. 2020 , 34, 95-103	16
133	Interaction of Cannabis Use and Aging: From Molecule to Mind. 2020 , 16, 140-176	4
132	Cannabinoids: A Guide for Use in the World of Gastrointestinal Disease. 2020 , 54, 769-788	1
131	The Cannabinoid Receptor Agonist WIN55,212-2 Ameliorates Hippocampal Neuronal Damage After Chronic Cerebral Hypoperfusion Possibly Through Inhibiting Oxidative Stress and ASK1-p38 Signaling. 2020 , 37, 847-856	7
130	Clindamycin inhibits nociceptive response by reducing tumor necrosis factor- α and CXCL-1 production and activating opioidergic mechanisms. 2020 , 28, 551-561	5
129	Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence. 2020 , 11, 859	16
128	The neuropharmacology of cannabinoid receptor ligands in central signaling pathways. 2020 ,	7
127	Chlorotrimethylsilane promoted one-flask heterocyclic synthesis of 1,2,4-triazoles from nitrilamines: Modeling studies and bioactivity evaluation of LH-21 and Rimonabant analogues. 2020 , 104, 104299	1
126	Cannflavins - From plant to patient: A scoping review. 2020 , 146, 104712	7
125	Naturally Occurring Cannabinoids and their Role in Modulation of Cardiovascular Health. 2020 , 17, 625-650	3
124	Use of Cannabinoids for the Treatment of OSA. 2020 , 6, 226-231	
123	Structural Insights into β -arrestin/CB1 Receptor Interaction: NMR and CD Studies on Model Peptides. 2020 , 21,	3
122	Cannabinoids-based Medicine Pharmacology, Drug Interactions, and Perioperative Management of Surgical Patients. 2020 , 38, 167-188	0
121	Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis. 2020 , 6, 21	10
120	Delta-9 THC can be detected and quantified in the semen of men who are chronic users of inhaled cannabis. 2020 , 37, 1497-1504	3
119	Cannabinoid Use in Musculoskeletal Illness: a Review of the Current Evidence. 2020 , 13, 379-384	4
118	Activation of CBR Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury. 2020 , 204, 3339-3350	7
117	Cannabidiol (CBD) and Tetrahydrocannabinol (THC) for chronic insomnia disorder (CANSLEEPQ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. 2020 , 10, e034421	10

116	Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. 2020 , 41, 1263-1271	23
115	Association of a Variant of Gene Encoding Cannabinoid Receptor 1 With Gilles de la Tourette Syndrome. 2020 , 11, 125	8
114	Recurrent priapism in the setting of cannabis use. 2020 , 2, 7	2
113	Improved identification of phytocannabinoids using a dedicated structure-based workflow. 2020 , 219, 121310	16
112	Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience. 2020 , 35, 100833	5
111	Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease. 2020 , 11, 1097	13
110	Cannabidiol Protects Dopaminergic Neurons in Mesencephalic Cultures against the Complex I Inhibitor Rotenone Via Modulation of Heme Oxygenase Activity and Bilirubin. 2020 , 9,	8
109	Acute and chronic effects of Tetrahydrocannabinol (THC) on cerebral blood flow: A systematic review. 2020 , 101, 109900	6
108	Design, microwave-assisted synthesis, biological evaluation and molecular modeling studies of 4-phenylthiazoles as potent fatty acid amide hydrolase inhibitors. 2020 , 95, 534-547	4
107	The therapeutic role of Cannabidiol in mental health: a systematic review. 2020 , 2, 2	21
106	Challenges and Opportunities in Preclinical Research of Synthetic Cannabinoids for Pain Therapy. 2020 , 56,	8
105	Terpenoids, Cannabimimetic Ligands, beyond the Plant. 2020 , 25,	30
104	Depression of Accumbal to Lateral Hypothalamic Synapses Gates Overeating. 2020 , 107, 158-172.e4	15
103	Antinociceptive and sedative activity of Vernonia patula and predictive interactions of its phenolic compounds with the cannabinoid type 1 receptor. 2021 , 35, 1069-1079	6
102	Antinociception mechanisms of action of cannabinoid-based medicine: an overview for anesthesiologists and pain physicians. 2021 , 46, 240-250	5
101	Endogenous antagonists of N-methyl-D-aspartate receptor in schizophrenia. 2021 , 17, 888-905	5
100	Opioid-sparing effects of cannabinoids: Myth or reality?. 2021 , 106, 110065	6
99	Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors. 2021 , 61, 441-463	17

98 Cannabinoids and Pain: Mechanisms of Action. **2021**, 191-204

97 Phytocannabinoids: Tetrahydrocannabinol (THC). **2021**, 71-77

2

96 Distinct Activity of Endocannabinoid-Hydrolyzing Enzymes MAGL and FAAH in Key Regions of Peripheral and Central Nervous System Implicated in Migraine. **2021**, 22,

5

95 The Endocannabinoid System and Alcohol Dependence: Will Cannabinoid Receptor 2 Agonism be More Fruitful than Cannabinoid Receptor 1 Antagonism?. **2021**,

4

94 Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses. **2021**, 13,

21

93 Modulation of Excitatory Synaptic Transmission During Cannabinoid Receptor Activation. **2021**, 1

92 NSAIDs, Opioids, and Beyond.

91 Cannabidiol Enhances Intestinal Cannabinoid Receptor Type 2 Receptor Expression and Activation Increasing Regulatory T Cells and Reduces Murine Acute Graft-versus-Host Disease without Interfering with the Graft-versus-Leukemia Response. **2021**, 377, 273-283

1

90 CB antagonism increases excitatory synaptogenesis in a cortical spheroid model of fetal brain development. **2021**, 11, 9356

4

89 Cannabidiol and the Canonical WNT/ β Catenin Pathway in Glaucoma. **2021**, 22,

3

88 Endocannabinoid system: Role in blood cell development, neuroimmune interactions and associated disorders. **2021**, 353, 577501

2

87 Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/ β catenin pathway. **2021**,

2

86 Potential role of cannabidiol in Parkinson's disease by targeting the WNT/ β catenin pathway, oxidative stress and inflammation. **2021**, 13, 10796-10813

3

85 Anti-inflammatory and antinociceptive effects of the selective cannabinoid CB receptor agonist ABK5. **2021**, 145, 319-326

2

84 Buprenorphine: Far Beyond the "Ceiling". **2021**, 11,

1

83 Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier. **2021**, 11,

15

82 Pro-Inflammatory Cytokines: Potential Links between the Endocannabinoid System and the Kynurenine Pathway in Depression. **2021**, 22,

3

81 The endocannabinoid system is modulated in reward and homeostatic brain regions following diet-induced obesity in rats: a cluster analysis approach. **2021**, 60, 4621-4633

3

80	Cannabinoid receptor agonists from Conus venoms alleviate pain-related behavior in rats. 2021 , 205, 173182	1
79	Biomarkers of non-infectious inflammatory CNS diseases in dogs: Where are we now? Part 2 - Steroid responsive meningitis-arteritis. 2021 , 273, 105692	1
78	Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases. 2021 , 22,	1
77	Receptor-Dependent and Independent Regulation of Voltage-Gated Ca Channels and Ca-Permeable Channels by Endocannabinoids in the Brain. 2021 , 22,	2
76	Cannabinoid receptor type 1 antagonists alter aspects of risk/reward decision making independent of toluene-mediated effects. 2021 , 1	
75	Cannabis and pain: a scoping review. 2021 ,	2
74	Early suppression of the endocannabinoid degrading enzymes FAAH and MAGL alters locomotor development in zebrafish. 2021 , 224,	2
73	Gamma-Aminobutyric Acid (GABA) and the Endocannabinoids: Understanding the Risks and Opportunities.	1
72	Female but not male rats show biphasic effects of low doses of Δ^9 -tetrahydrocannabinol on anxiety: can cannabidiol interfere with these effects?. 2021 , 196, 108684	4
71	Anxiety, depression-like behaviors and biochemistry disorders induced by cannabis extract in female mice. 2021 , 28, 6097-6111	0
70	Cannabinoids as anticancer and neuroprotective drugs: Structural insights and pharmacological interactionsA review. 2021 , 111, 9-31	1
69	Forensic Chemistry. 2022 ,	0
68	The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R). 2021 , 1-23	0
67	Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders. 2021 , 18, 217-227	6
66	Δ^9 -tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR. 2021 , 61, e57-e60	5
65	Endocannabinoid-Like Lipids in Plants. 1-9	2
64	Cannabinoid Modulation of Dopaminergic Circuits in Neurodegenerative and Neuropsychiatric Disorders. 2013 , 73-101	1
63	Cannabinoids for Treatment of MS Symptoms: State of the Evidence. 2018 , 18, 50	47

62	Clinical Toxicology. 2012 , 1109-1188	2
61	From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis. 2021 , 64, 385-403	5
60	Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. 2020 , 10, 158	19
59	Combination of magnetic solid-phase extraction with dispersive liquid-liquid microextraction followed by GC-MS for trace analysis of synthetic cannabinoids in plasma samples. 2020 , 15, 545-549	1
58	Periprandial response of central cannabinoid system to different feeding conditions in rainbow trout. 2020 , 1-12	3
57	Blockage of ventrolateral periaqueductal gray matter cannabinoid 1 receptor increases dental pulp pain and pain-related subsequent learning and memory deficits in rats. 2020 ,	1
56	Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice. 2011 , 6, e25856	56
55	The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonists. 2013 , 8, e77739	26
54	The Effect of CB1 Antagonism on Hepatic Oxidative/Nitrosative Stress and Inflammation in Nonalcoholic Fatty Liver Disease. 2021 , 28, 169-180	6
53	Insight into Pain Modulation: Nociceptors Sensitization and Therapeutic Targets. 2019 , 20, 775-788	20
52	Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. 2019 , 17, 947-960	13
51	The "Entourage Effect": Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders. 2020 , 18, 87-96	47
50	Opioid and endocannabinoid system in orofacial pain. 2019 , 68, 705-715	8
49	Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals. 2020 , 22,	8
48	Functional role of cannabinoid receptors in urinary bladder. 2010 , 26, 26-35	17
47	Pharmacotherapies for Overeating and Obesity. 2013 , 4, 131	9
46	Pharmacological Mechanism of Paracetamol on Empathy-Like Behavior in Adult Male Rats.	
45	Hematopoietic Stem Cell Mobilization: Current Collection Approaches, Stem Cell Heterogeneity, and a Proposed New Method for Stem Cell Transplant Conditioning. 2021 , 17, 1939-1953	

- 44 Innovative Clinical-Organizational Model to Ensure Appropriateness and Quality in the Management of Medical Cannabis: An Italian Regional Case. **2021**, 9, 1
- 43 Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. **2021**, 4
- 42 Endocannabinoid Functions in Neurogenesis, Neuronal Migration, and Specification. **2008**, 237-256
- 41 WIN 55212 2. **2008**, 1-4
- 40 Chatper 17: The EC System and Central Control of Energy Balance: The Nucleus Accumbens. **2008**, 143-150
- 39 The Effects of Cannabinoids on Immune Cells, Responses and Diseases. **2012**, 307-359
- 38 Central Analgesic Activity. **2014**, 1-104
- 37 Cardiovascular Consequences of Addiction. **2015**, 1577-1609
- 36 Hepatic Targeting: Physiological Basis and Design Strategy. **2015**, 197-238
- 35 Long-term Administration of Cannabis sativa Impairs Learning and Memory in CD1 Mice. **2015**, 15, 155-159
- 34 Central Analgesic Activity. **2016**, 1785-1874
- 33 Cannabidiol Decades of research and current clinical uses. **2019**, 4, 10
- 32 Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis. 1
- 31 The endocannabinoid system as a target for obesity treatment. **2008**, 69-80
- 30 Parkinson's disease related alterations in cannabinoid transmission. **2021**, 178, 82-96 0
- 29 Neuroinflammation, Early-Life Adversity, and Brain Development.. **2022**, 30, 24-39 5
- 28 Analytical Methods for Herbal Products Containing Synthetic Cannabinoids: A Review. **2022**, 27, 100396 0
- 27 Neuroprotection of retinal ganglion cells using the activation of the endogenous cannabinoid signaling system in mammalian eyes.. **2022**, 6, NS20210038 0

- 26 Use of computational toxicology tools to predict endpoints associated with Mode of Action and the endocannabinoid system: A case study with chlorpyrifos, chlorpyrifos-oxon and Tetrahydrocannabinol.. **2022**, 3, 100064 1
- 25 Pharmacological antagonization of cannabinoid receptor 1 improves cholestasis in Abcb4 mice.. **2021**, 0
- 24 Cannabinoids and sleep. **2022**,
- 23 A critical review of cannabis in medicine and dentistry: A look back and the path forward.. **2022**, 0
- 22 Medical marijuana for inflammatory bowel disease: the highs and lows.. **2021**, 1-9 0
- 21 Components of the Endogenous Cannabinoid System as Potential Biomarkers for Interstitial Cystitis/Bladder Pain Syndrome.. **2021**, 12, 0
- 20 Effects of Marijuana Use in Patients with Orthopaedic Trauma.. **2021**, 9,
- 19 Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain.. **2022**, 23, 1
- 18 Table_1.xlsx. **2020**,
- 17 E-cigarette or vaping use-associated lung injury. **2022**, 100, 52-61
- 16 Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies.
- 15 Chronic Cannabis Intoxication and Propofol-Induced Salivation: Causes and Considerations. **2022**, 29, 223-232
- 14 Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. 2
- 13 Elucidation of partial activation of cannabinoid receptor type 2 and identification of potential partial agonists: Molecular dynamics simulation and structure-based virtual screening. **2022**, 99, 107723 11
- 12 Cannabinoid Type 1 Receptors in the Basolateral Amygdala Regulate ACPA-Induced Place Preference and Anxiolytic-Like Behaviors. 0
- 11 Fatty Acid Amide Hydrolase Deficiency Is Associated with Deleterious Cardiac Effects after Myocardial Ischemia and Reperfusion in Mice. **2022**, 23, 12690 0
- 10 Cannabis-Based Medicinal Products in the Management of Emotionally Unstable Personality Disorder (EUPD): A Narrative Review and Case Series. **2022**, 12, 1467 0
- 9 The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R). **2022**, 565-587 0

- 8 Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. **2022**, 2022, 1-14 o
- 7 Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment. **2022**, 12, 2117 o
- 6 ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. rapm-2022-104013 o
- 5 Antitumorigenic Effect of Cannabidiol in Lung Cancer: What Do We Know So Far? A Mini Review. **2022**, 26, 406-413 o
- 4 Development of Yin-Yang ligand for cannabinoid receptors. **2023**, 133, 106377 o
- 3 The Endogenous Cannabinoid and the Nitricoxidergic Systems in the Modulation of Stress Responses. **2023**, 24, 2886 o
- 2 The evolution of cannabinoid receptors in cancer. o
- 1 Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain. **2023**, 24, o